2C-D

2C-D

2C-D

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

2C-D

Also known as:

  • 2-(2,5-Dimethoxy-4-methylphenyl)ethanamin[German][ACD/IUPAC Name]
  • 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine[ACD/IUPAC Name]
  • 2-(2,5-Diméthoxy-4-méthylphényl)éthanamine[French][ACD/IUPAC Name]
  • 2,5-dimethoxy-4-methyl-phenethylamine
  • 2,5-Dimethoxy-4-Methylphenethylamine
  • 2,5-dimethoxy-4-methyl-β-phenethylamine
  • Benzeneethanamine, 2,5-dimethoxy-4-methyl-[ACD/Index Name]
  • 2-(2,5-dimethoxy-4-methyl-phenyl)ethanamine
  • 2-(2,5-dimethoxy-4-methyl-phenyl)ethylamine
  • 2-(2,5-Dimethoxy-4-methyl-phenyl)-ethylamine
  • 2,5-Dimethoxy-4-methylbenzeneethanamine
  • 2,5-Dimethoxy-4-methylphenethylamine Hydrochloride
  • 2,5-Dimethoxy-4-methylphenylethylamine
  • 2C-D
  • 4-Methyl-2,5-di-meo-pea
  • 4-Methyl-2,5-Dimethoxyphenethylamine
  • CHEMBL124049
  • phenethylamine, 2,5-dimethoxy-4-methyl-

A fairly generic psychedelic famed for being usable as “psychedelic tofu”. Little character of its own but pleasant in combinations.

Summary

Its sensory and cognitive effects profile has been described as being the most similar to that of mescaline among members of the 2C-x family, albeit with a significantly shorter duration. The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences. Initial trials by Alexander Shulgin at sub-threshold doses in humans were carried out in 1964.

Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related psychedelic phenethylamines. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased. Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential nootropic, albeit with mixed results.

Today, 2C-D is used both recreationally and as an entheogen. It is rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.

History

Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978. The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of DOM. Shulgin notably referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with. While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged psychedelic in its own right. Despite showing promise as a very functional psychostimulant with successful studies investigating the use in psychotherapy in Germany, 2C-D has not found widespread use.

This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines. Of these, it tends to be substantially harder to find and notably more expensive by weight.

Chemistry

2C-D

2C-D

2C-D contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4 of the phenyl ring. 2C-D belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.

Common Name2,5-Dimethoxy-4-Methylphenethylamine
Systematic name2,5-Dimethoxy-4-Methylphenethylamine
FormulaC_{11}H_{17}NO_{2}
SMILESCc1cc(c(cc1OC)CCN)OC
Std. InChiInChI=1S/C11H17NO2/c1-8-6-11(14-3)9(4-5-12)7-10(8)13-2/h6-7H,4-5,12H2,1-3H3
Std. InChiKeyUNQQFDCVEMVQHM-UHFFFAOYSA-N
Avg. Mass195.2582 Da
Molecular Weight195.2582
Monoisotopic Mass195.125931 Da
Nominal Mass195
ChemSpider ID119559

Subscribe for the latest updates

Dosing Guide

Oral
Threshold3-4mg
Light5-15mg
Common20-50mg
Strong50-100mg

Duration

2C-D Duration Data
Onset15-45 minutes
Duration3-5 hours
After-effects1-8 hours

Interactions and Synergies

Caution

  1. Mescaline
  2. DOx
  3. NBOMes
  4. 2C-T-x
  5. 5-MeO-xxT
    • The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics
  6. Cannabis
    • Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
  7. Amphetamines
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  8. Cocaine
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  9. MAOIs
    • MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably

Dangerous

  1. Tramadol
    • Tramadol is well known to lower seizure threshold and psychedelics raise the risk of seizures.

No Synergy

  1. Caffeine
    • High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating the combination may cause some physical discomfort.
  2. Opioids

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effectscomparable to 2C-B, mental and physical stimulation, mood lift, euphoria, cognitive enhancement, increased mental clarity and interest, feelings of empathy, enhanced tactile sensation, sensory enhancement, brightened colors, sociability, introspection, giggling, pupil dilation, increased heart rate, changes in perception of time, stomach discomfort, headache, dizziness, anxiety
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

2C-D’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective Effects

The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.

Physical Effects

Psychological Effects

Visual Effects

Compared to other members of the 2C-x family like 2C-B, the visual effects of 2C-D have been noted for being understated until heavier doses are reached. After this point, a full spectrum of hallucinatory visual phenomena begin to appear.

Enhancements

Distortions

Geometry

The visual geometry of 2C-D be described as more similar in appearance to that of DOM or 25D-NBOMe than that of LSD, 2C-B or 2C-I. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of level 8B visual geometry over level 8A.

Hallucinatory states

Auditory Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

Legal Status

  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
  • Austria: 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
  • Canada: 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
  • China: 2C-D is a controlled substance in China as of October 2015.
  • Denmark: 2C-D is added to the list of Schedule B controlled substances.
  • Germany: 2C-D is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Japan: 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
  • Latvia: 2C-D is a Schedule I controlled substance.
  • Sweden: 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.
  • Switzerland: Possession, production and sale is illegal.
  • United Kingdom: 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
  • United States: 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.

  • References

    1. Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084
    2. Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
    3. Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml
    4. Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084
    5. Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
    6. Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397
    7. King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6(7–8), 808–818. https://doi.org/10.1002/dta.1570
    8. Schneider, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich. Würzbug, Germany: Königshausen & Neumann. No complete fulltext was available at the time of writing, please refer to the Google Scholar document: https://books.google.de/books?id=yo45tYQj2-MC&lpg=PA129&ots=tW1EqmhrGF&dq=DMM-PEA&hl=de&pg=PA129&output=embed.
    9. Martin, J. (2014). Drugs on the Dark Net. London: Palgrave Macmillan UK. https://doi.org/10.1057/9781137399052
    10. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    11. New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New Psychoactive Substances.pdf
    12. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    13. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
    14. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
    15. Bekendtgørelse om euforiserende stoffer | https://www.retsinformation.dk/Forms/R0710.aspx?id=137169
    16. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    17. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    18. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    19. Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
    20. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
    21. Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
    22. http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
    23. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made
    24. S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.